An antibody designed to neutralize sMIC and clear sMIC levels without blocking NKG2D activation restored NK cell anti-tumor activity in mouse models of melanoma and prostate cancer [141, 142]. This evidence concerns the gene KLRK1 and prostate carcinoma.